FDA Approves FLONASE® Sensimist™ Allergy Relief. Another Rx-to-OTC Switch from GSK Consumer Healthcare to help allergy sufferers find more complete relief.
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK (LSE/NYSE: GSK) today announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
Agreement further strengthens respiratory pipeline of targeted biological therapies
- First-to-market with quadrivalent vaccine
- Company to deliver up to 40 million doses
Prize recognizes innovations that are helping reduce child deaths
This year’s Healthcare Innovation Award gives special attention to innovations which focus on the hardest-to-reach children
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been assessing how we can best help to respond. The World Health Organization has declared Zika and the increase in neurological disorders and neonatal malformations associated with it to be a public health emergency of international concern.
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients
Read more - FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients Read more